Skip to content
Research Article Open access CC BY 4.0

Egypt Fights Spinal Muscular Atrophy

Omar Elsaka, Moneer Ayman Noureldean, Mohamed Adel Gamil, Mostafa Tarek Ghazali, Ashraf Hamada Abd Al-Razik, Dalia Hisham

Asian Journal of Research and Reports in Neurology · pp. 168–170 · Published 21 Dec 2021

Abstract

SMA (spinal muscular atrophy) is a neuromuscular illness caused by a genetic (inherited) mutation that causes muscles to weaken and waste away. Motor neurons, a type of nerve cell in the spinal cord that controls muscle movement, are lost in people with SMA. Many pharmaceutical companies continue to invest heavily in research into SMA therapies. Many additional prospective medications, such as valproic acid, phenylbutyrate, hydroxyurea, albuterol, gabapentin, riluzole, olesoxime, and rapamycin, have failed to generate adequate outcomes regarding disease progression.

Spinal muscular atrophy medications hydroxyurea neuromuscular illness.

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.